Popular

Less than a month removed from acquiring rights to a cutting edge nano and micro particle entrapment technology, Plandaí Biotechnology, Inc. (OTCQB – PLPL) has already secured a lucrative out-licensing agreement that could be worth millions in revenue over the next 5 years.

The company’s new advancements could lead to new product introductions and revenue in areas not contemplated by us previously, thus enhancing the value that much more.

For investors seeking a well-positioned mid-late stage biotechnology company, one may not need to go any further than Nuvilex, Inc. (OTCQB – NVLX - $0.135 – Spec Buy). The Company has nearly all of the characteristics biotech and micro cap investors find attractive and actively seek.

With a great deal of experience in protocol design, Nuvilex management is well on its way to designing, compiling, and completing the necessary steps in order to move forward as quickly as possible.

The Company released news that should have been received by investors as its most significant event to date, excluding the acquisition of rights to the ground-breaking live-cell encapsulation technology to treat cancer. Instead, it was treated as a ho-hum event. Here’s why investors that missed the significance will be caught napping.

Global Payout, Inc. is at the apex of the huge global electronic payments and prepaid card industry.